Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYingying WuZCZhipeng ChengAZAo Zhang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows high efficacy and tolerability of polatuzumab vedotin regimens in newly diagnosed diffuse large B-cell lymphoma patients, indicating promising treatment options.

Key Points

  • Polatuzumab vedotin regimens achieve a 90.5% overall response rate in newly diagnosed diffuse large B-cell lymphoma patients.
  • The Pola-R-CHP regimen shows a complete response rate of 76.7% among treated patients, highlighting effective outcomes.
  • Analysis of clinical data from 42 patients treated with Pola regimens indicates manageable adverse events and safety.
  • Findings suggest that polatuzumab vedotin may offer effective treatment options for high-risk subgroups in diffuse large B-cell lymphoma.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e28fhttps://doi.org/10.1182/blood-2025-7207
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The efficacy and safety of polatuzumab vedotin-based regimens in the treatment of diffuse large B-cell lymphoma: A retrospective real-world study2025
  2. 2Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data2025
  3. 3A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China2025
  4. 4Effectiveness and safety profile of pola-based regimen in DLBCL Patients with high-risk factors in real world: A retrospective study in China2025
  5. 5Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China2025